A systematic review on the effect of bevacizumab in exudative age-related macular degeneration

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 247, Issue 1, 2009, Pages 1-11

  Schouten, Jan S A G ^a   Heij, Ellen C ^a   Webers, Carroll A B ^a   Lundqvist, Igor J ^a   Hendrikse, Fred ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Bevacizumab; Exudative macular degeneration; Retinal thickness; Systematic review; Visual acuity

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; TRIAMCINOLONE;

ANTERIOR EYE CHAMBER INFLAMMATION; BLURRED VISION; CATARACT; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COCHRANE LIBRARY; CONJUNCTIVAL HEMORRHAGE; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; EMBASE; ENDOPHTHALMITIS; EVIDENCE BASED PRACTICE; EYE DISEASE; EYE INFLAMMATION; HEART INFARCTION; HUMAN; INCIDENCE; INTRAOCULAR HEMORRHAGE; INTRAOCULAR PRESSURE; MEDLINE; OPTICAL COHERENCE TOMOGRAPHY; PERIPHERAL VASCULAR DISEASE; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; REPEATED DRUG DOSE; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINA PIGMENT EPITHELIOPATHY; RETINA TEAR; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; SYSTEMIC DISEASE; SYSTOLIC BLOOD PRESSURE; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; UVEITIS; VISUAL ACUITY; VITREOUS BODY DETACHMENT; VITREOUS DISEASE;

AGING; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; HUMANS; MACULAR DEGENERATION; VISUAL ACUITY;

EID: 56949108327     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-008-0952-y     Document Type: Review

References (48)

1. Abraham Marin ML, Cortes Luna CF, Alvarez Rivera G, Hernandez Rojas M, Quiroz Mercado H, Morales Canton V (2006) Intravitreal bevacizumab therapy for neovascular age-related macular degeneration: A pilot study. Graefes Arch Clin Exp Ophthalmol 245:651-655, doi: 10.1007/ s00417-006-0411-6
2. Aggio FB, Farah ME, Silva WC, Melo GB (2006) Intravitreal bevacizumab for exudative age-related macular degeneration after multiple treatments. Graefes Arch Clin Exp Ophthalmol 245:215-220, doi: 10.1007/ s00417-006-0412-5
3. Aisenbrey S, Ziemssen F, Volker M, Gelisken F, Szurman P, Jaissle G et al (2006) Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 245:941-948, doi: 10.1007/s00417-006-0471-7
4. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ (2006) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113:363-372, doi: 10.1016/ j.ophtha.2005.11.019
5. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ (2007) Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 114:2179-2182, doi: 10.1016/j.ophtha.2007.09.012
6. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ (2007) Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 114:855-859, doi: 10.1016/j.ophtha.2007.01.017
7. Bashshur ZF, Bazarbachi A, Schakal A, Haddad ZA, El Haibi CP, Noureddin BN (2006) Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 142:1-9, doi: 10.1016/j.ajo.2006.02.037
8. Bashshur ZF, Haddad ZA, Schakal A, Jaafar RF, Saab M, Noureddin BN (2008) Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: A one-year prospective study. Am J Ophthalmol 145:249-256, doi: 10.1016/j.ajo.2007.09.031
9. Bashshur ZF, Schakal A, Hamam RN, El-Haibi CP, Jaafar RF, Noureddin BN (2007) Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degeneration. Arch Ophthalmol 125:1357-1361, doi: 10.1001/archopht.125.10.1357
10. Bolz M, Michels S, Geitzenauer W, Prager F, Schmidt Erfurth U (2006) Effect of systemic bevacizumab therapy on retinal pigment epithelial detachment. Br J Ophthalmol 91:785-789, doi: 10.1136/bjo.2006.102467
11. Bressler NM, Bressler SB, Congdon NG, Ferris FLr, Friedman DS, Klein R, Lindblad AS, Milton RC, Seddon JM, Age-Related Eye Disease Study Research Group (2003) Potential public health impact of age-related eye disease study results: AREDS report no. 11. Arch Ophthalmol 121:1621-1624, doi: 10.1001/archopht.121.11.1621
12. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S, ANCHOR-Study-Group (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432-1444, doi: 10.1056/NEJMoa062655
13. Brown MM, Brown GC, Sharma S, Stein JD, Roth Z, Campanella J et al (2006) The burden of age-related macular degeneration: A value-based analysis. Curr Opin Ophthalmol 17:257-266
14. Carvounis PE, Kopel AC, Benz MS (2007) Retinal pigment epithelial tears following ranibizumab for exudative age-realted macualr degeneration. Am J Ophthalmol 143:504-505, doi: 10.1016/j.ajo.2006.11.028
15. Chen CY, Wong TY, Heriot WJ (2007) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: A short-term study. Am J Ophthalmol 143:510-512, doi: 10.1016/j.ajo.2006.10.004
16. Chen E, Kaiser RS, Vander JF (2007) Intravitreal bevacizumab for refractory pigment epithelial detachment with occult choroidal neovascularization in age-related macular degeneration. Retina 27(4):445-450
17. Cleary CA, Jungkim S, Ravikumar K, Kelliher C, Acheson RW, Hickey-Dwyer M (2008) Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6- and 9-month results. Eye 22:82-86, doi: 10.1038/sj.eye.6702936
18. Emerson MV, Lauer AK, Flaxel CJ, Wilson DJ, Francis PJ, Stout JT et al (2007) Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration. Retina 27:439-444, doi: 10.1097/ IAE.0b013e31804b3e15
19. Falkenstein IA, Cheng L, Morrison VL, Kozak I, Tammewar AM, Freeman WR (2007) Standardized visual acuity results associated with primary versus secondary bevacizumab (avastin) treatment for choroidal neovascularization in age-related macular degeneration. Retina 27:701-706, doi: 10.1097/IAE.0b013e3180654240
20. Falkenstein IA, Cochran DE, Azen SP, Dustin L, Tammewar AM, Kozak I et al (2008) Comparison of visual acuity in macular degeneration patients measured with Snellen and early treatment diabetic retinopathy study charts. Ophthalmology 115:319-323
21. Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ, Puliafito CA, Davis JL, Flynn HW, Esquiabro M (2007) An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 143:566-583
22. Fung AE, Rosenfeld PJ, Reichel E (2006) The International Intravitreal Bevacizumab Safety Survey: Using the internet to assess drug safety worldwide. Br J Ophthalmol 90:1344-1349, doi: 10.1136/bjo.2006.099598
23. Geitzenauer W, Michels S, Prager F, Kornek G, Vormittag L, Rosenfeld P et al (2006) Early effects of systemic and intravitreal bevacizumab (AvastinR) therapy for neovascular age-related macular degeneration. Klin Monatsblat Augenheilkund 223:822-827, doi: 10.1055/s-2006-926875
24. Gelisken F, Inhoffen W, Partsch M, Schneider U, Kreissig I (2001) Retinal pigment epithelial tear after photodynamic therapy for choroidal neovascularization. Am J Ophthalmol 131:518-520, doi: 10.1016/ S0002-9394(00)00813-8
25. Giansanti F, Virgili G, Bini A, Rapizzi E, Giacomelli G, Donati MC et al (2007) Intravitreal bevacizumab therapy for choroidal neovascularization secondary to age-related macular degeneration: 6-month results of an open-label uncontrolled clinical study. Eur J Ophthalmol 17:230-237
26. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR, VEGF-Inhibition-Study-in-Ocular-Neovascularization-Clinical-Trial-Group (2004) Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351:2805-2816, doi: 10.1056/NEJMoa042760
27. Hahn R, Sacu S, Michels S, Varga A, Weigert G, Geitzenauer W et al (2007) [Intravitreal bevacizumab versus verteporfin and intravitreal triamcinolone acetonide in patients with neovascular age-related macula degeneration]. Ophthalmologe 104(7):588-593
28. Kliffen M, Sharma HS, Mooy CM, Kerkvliet S, de-Jong PT (1997) Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol 81:154-162
29. Ladewig MS, Ziemssen F, Jaissle G, Helb HM, Scholl HPN, Eter N et al (2006) Intravitreal bevacizumab for neovascular age-related macular degeneration. Ophthalmologe 103:463-470, doi: 10.1007/s00347-006-1352-5
30. Lazic R, Gabric N (2007) Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 245:68-73, doi: 10.1007/s00417-006-0466-4
31. Lazic R, Gabric N (2007) Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Ophthalmology 114:1179-1185, doi: 10.1016/j.ophtha.2007.03.006
32. Lazic R, Gabric N, Dekaris I, Saric B, Gavric M (2007) Intravitreal bevacizumab (Avastin) in treatment of neovascular age-related macular degeneration. Coll Antropol 31:77-81
33. Madhusudhana KC, Hannan SR, Williams CP, Goverdhan SV, Rennie C, Lotery AJ et al (2007) Intravitreal bevacizumab (Avastin) for the treatment of choroidal neovascularization in age-related macular degeneration: results from 118 cases. Br J Ophthalmol 91:1716-1717, doi: 10.1136/ bjo.2006.108639
34. Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS (2005) Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: Twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 112:1035-1047, doi: 10.1016/ j.ophtha.2005.02.007
35. Moshfeghi AA, Rosenfeld PJ, Puliafito CA, Michels S, Marcus EN, Lenchus JD, Venkatraman AS (2006) Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: Twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology 113:2002 e2001-2012
36. Mulcahy MF, Benson AB (2005) Bevacizumab in the treatment of colorectal cancer. Expert Opin Biol Ther 5:997-1005, doi: 10.1517/14712598.5.7.997
37. Rich RM, Rosenfeld PJ, Puliafito CA, Dubovy SR, Davis JL, Flynn HW et al (2006) Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 26:495-511, doi: 10.1097/01.iae.0000225766.75009.3a
38. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, MARINA Study Group (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419-1431, doi: 10.1056/ NEJMoa054481
39. Sackett DL, Haynes RB, Guyatt GH, Tugwell P (1991) Clinical epidemiology. A basic science for clinical medicine. Little, Brown and Company, Boston
40. Spaide RF, Laud K, Fine HF, Klancnik JM Jr, Meyerle CB, Yannuzzi LA et al (2006) Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26:383-390, doi: 10.1097/00006982-200604000-00001
41. Stifter E, Michels S, Prager F, Georgopoulos M, Polak K, Hirn C et al (2007) Intravitreal bevacizumab therapy for neovascular age-related macular degeneration with large submacular hemorrhage. Am J Ophthalmol 144:886-892, doi: 10.1016/j.ajo.2007.07.034
42. Sund NJ, Lai MM, Capone A Jr et al (2007) Efficacy of intravitreal bevacizumab (AvastinTM) vs ranibizumab (LucentisTM) as first-line monotherapy for the treatment of neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 48:E-Abstract 1813
43. Takeda AL, Colquitt J, Clegg AJ, Jones J (2007) Pegabtanib and ranibizumab for neovascular age-related macular degeneration: A systematic review. Br J Ophthalmol 91:1177-1182, doi: 10.1136/ bjo.2007.118562
44. Verhagen AP, de Vet HC, de Bie RA, Kessels AG, Boers M, Bouter LM et al (1998) The Delphi list: A criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol 51:1235-1241, doi: 10.1016/ S0895-4356(98)00131-0
45. VISION Clinical Trial Group (2006) Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 113:1508-1521
46. Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, Arevalo JF, Berrocal MH, Farah ME, Maia M, Roca JA, Rodriguez FJ, Pan-American Collaborative Retina Study Group (Pacores) (2007) Twelve-month safety of intravitreal injections of bevacizumab (Avastin): Results of the Pan-American Collaborative Retina Study Group (Pacores). Graefes Arch Clin Exp Ophthalmol 246(1):81-87
47. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL et al (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427-434, doi: 10.1056/NEJMoa021491
48. Yoganathan P, Deramo VA, Lai JC, Tibrewala RK, Fastenberg DM (2006) Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration. Retina 26:994-998, doi: 10.1097/01.iae.0000244380.34082.67